Your browser doesn't support javascript.
loading
An unnatural amino acid dependent, conditional Pseudomonas vaccine prevents bacterial infection.
Pigula, Michael; Lai, Yen-Chung; Koh, Minseob; Diercks, Christian S; Rogers, Thomas F; Dik, David A; Schultz, Peter G.
Afiliação
  • Pigula M; Department of Chemistry, Scripps Research, La Jolla, CA, USA.
  • Lai YC; Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.
  • Koh M; Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
  • Diercks CS; Department of Chemistry, Pusan National University, Busan, Korea.
  • Rogers TF; Department of Chemistry, Scripps Research, La Jolla, CA, USA.
  • Dik DA; Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.
  • Schultz PG; Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Nat Commun ; 15(1): 6766, 2024 Aug 08.
Article em En | MEDLINE | ID: mdl-39117651
ABSTRACT
Live vaccines are ideal for inducing immunity but suffer from the need to attenuate their pathogenicity or replication to preclude the possibility of escape. Unnatural amino acids (UAAs) provide a strategy to engineer stringent auxotrophies, yielding conditionally replication incompetent live bacteria with excellent safety profiles. Here, we engineer Pseudomonas aeruginosa to maintain auxotrophy for the UAA p-benzoyl-L-phenylalanine (BzF) through its incorporation into the essential protein DnaN. In vivo evolution using an Escherichia coli-based two-hybrid selection system enabled engineering of a mutant DnaN homodimeric interface completely dependent on a BzF-specific interaction. This engineered strain, Pa Vaccine, exhibits undetectable escape frequency (<10-11) and shows excellent safety in naïve mice. Animals vaccinated via intranasal or intraperitoneal routes are protected from lethal challenge with pathogenic P. aeruginosa PA14. These results establish UAA-auxotrophic bacteria as promising candidates for bacterial vaccine therapy and outline a platform for expanding this technology to diverse bacterial pathogens.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pseudomonas aeruginosa / Infecções por Pseudomonas / Vacinas contra Pseudomonas Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pseudomonas aeruginosa / Infecções por Pseudomonas / Vacinas contra Pseudomonas Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article